Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 17c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.63), $0.17 better than the analyst estimate of ($0.80).

“I am pleased with the significant progress we have made in the third quarter across our commercial, regulatory, and clinical initiatives,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We are preparing for a potential launch of lumateperone in the first quarter of 2020, and continue to advance our clinical programs, including our PDE1 program and our Phase 3 trial evaluating lumateperone as an adjunctive therapy in bipolar depression.”

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance